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Chinese herbal product (CHP) is the major type of traditional Chinese medicine (TCM) and widely used to
relief the symptom of colorectal cancer. The aim of the study was to analyze the utilization of CHP for
treating patients with colorectal cancer in Taiwan. The usage of CHP, frequency of services, and pre-
scription pattern for colorectal cancer were analyzed from a randomly sampled cohort of 1 million
beneﬁciaries from the National Health Insurance Research Database. The odds ratios for utilization of
CHP were estimated with logistic regression model. 2846 patients were newly diagnosed as colorectal
cancer during 1998e2008 in the million cohort in Taiwan. 42.7% (n ¼ 1214) of them used CHP. Colorectal
cancer was the most common diagnosis coded by TCM doctor, followed by symptoms, signs, and ill-
deﬁned conditions. Costusroot and Amomum Six Gentlemen Decoction (香砂六君子湯 xiang sha liù
jun zǐ tang) was the most frequently prescribed formula for treating colorectal cancer. Among the top 10
most frequently prescribed CHP for treating colorectal cancer, six containing Ginseng Radix (人參, Panax
ginseng) and two containing Astragali Radix (黃耆, Astragalus membranaceus), which are reported to have
potential beneﬁcial synergistic effects on colorectal cancer cells. CHP containing Ginseng Radix or
Astragali Radix are the most frequently prescribed for colorectal cancer and their effects should be taken
into account by healthcare providers.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) remains one of the most prevalent
cancers and a leading cause of cancer related death world-wide.1e3
Despite the lack of solid evidence supporting their therapeutic
beneﬁts, the reported incidences of use of complementary and
alternative medicines (CAM) from the time of initial diagnosis of
colorectal cancer until his or her death (colorectal cancer survivors)ated Medicine, China Medical
, Taiwan.
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).
et al., Demographic and med
database study in Taiwan, Jrange from 70 to 86%.4 Attempting to improve one's physical and
emotional health,5e7 the desire to exert a sense of personal control
over one's illness,8 dissatisfaction with the medical care system or
health providers,9 and doubts concerning the effectiveness of
conventional treatment may be the reasons why patients use a
wide range of CAM including herbs, vitamins, homeopathic rem-
edies, and CHP.5,10 The expectations of CAM use varies among in-
dividuals. Some just hope to strengthen their immune system,
some expect to decrease the treatment-associated toxicity, and
some want to alleviate the CRC-derived symptoms.11e13 However,
there is no compelling evidence supporting the effectiveness of
CAM use in CRC survivors. In view of such and without further
knowledge on how effective CAM is, it is not easy for oncologists or
CAM practitioners to provide an appropriate recommendation that
can meet the expectations of CRC survivors.rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
ication characteristics of traditional Chinese medicine users among
ournal of Traditional and Complementary Medicine (2016), http://
C.-T. Wu et al. / Journal of Traditional and Complementary Medicine xxx (2016) 1e72TCM, a long and widely used form of medical care in ethnic
Chinese communities and nearby regions, which includes
acupuncture, traumatology manipulative therapies and Chinese
herbal products, has been growing in popularity and has offered an
important alternative or complement to health care in many
countries. Previous studies have disclosed that the potential
beneﬁcial anticancer effects of the usage of Ginseng Radix14 or
Astragali Radix15 among CRC survivors. Although a previous ran-
domized clinical trial of a CHP indicated that PHY 906 decrease in
CRC survivors' nausea and diarrhea effectively,16 the utilization of
individual CHP has rarely been reported. In Taiwan, CHP have been
an important part of health care for hundreds of years and over ten
thousands licensed CHPs are reimbursed under the current Na-
tional Health Insurance (NHI) system.
Taiwan launched a single-payer National Health Insurance
Program onMarch 1,1995. As of 2007, 22.60million of 22.96million
Taiwan populations were enrolled in this program. The database of
this program contains registration ﬁles, and original claim data for
reimbursement. National Health Insurance Research Database
(NHIRD) derived from this system by the Bureau of National Health
Insurance, Taiwan (BNHI) and maintained by the National Health
Research Institutes, Taiwan (NHRI), is provided to scientists in
Taiwan for research purposes. Accordingly, the claims database
provides a platform for understanding the utilization of CHP pre-
scribed by licensed TCM doctors. The aim of our study is to analyzea, NHIRD: National Health Insurance Research Database
products. 
Cases of colorectal
cancer, N = 3,558
CHP
N =
One million random
sample of NHIRDa
N = 1,000,000
CHPc users,
N = 1,214
Cases of colorectal
cancer, N = 3,860
New cases of colorectal
cancer, N = 2,846
Fig. 1. Flowchart of recruitment of subjects from the one million random sample of
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dx.doi.org/10.1016/j.jtcme.2016.07.001a random sample of this comprehensive database and to determine
the CHP utilization patterns for CRC survivors in Taiwan. Results of
this study may provide valuable information for physicians,
enabling them to respond to patients' use of CHP in an informed
way and strengthening the patient-physician relationship in CRC
care.
2. Materials and methods
2.1. Data resource
Our study protocols were approved by the Institutional Review
Board of the Ministry of Health and Welfare (MOHW), Taiwan. Our
population-based study retrospectively analyzed the reimburse-
ment records of 1 million NHI beneﬁciaries in the NHIRD that had
been previously selected at random from the 22 million beneﬁ-
ciaries of the NHI to determine the prevalence of prescribed CHP in
CRC survivors between January 1, 1998, and December 31, 2008, in
Taiwan. The electronic records of the NHIRD use beneﬁciary iden-
tiﬁcation numbers that are encrypted and maintained by NHRI of
Taiwan.17,18
The NHIRD records contain demographic information, including
age and sex, and clinical data, including all records of clinical visits
and hospitalizations and all information regarding prescribed drugs
and dosages, including CHPs, and three major diagnoses coded in; b, CRC: colorectal cancer; c, CHP: Chinese herbal 
 non-users,
1,632
Exclusion of cases without
colorectal cancer,
N = 996,140
Exclusion of prevalent cases
of other cancers before the 
date of CRCb diagnosis, N=
302
Exclusion of prevalent cases
of colorectal cancer before the
end of 1997, N = 712
the National Health Insurance Research Database from 1998 to 2008 in Taiwan.
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Modiﬁcation (ICD-9-CM) format.19
The participant selection from the NHIRD was performed as
shown in Figure 1. First, we excluded all beneﬁciaries without
colorectal cancer (n ¼ 996, 140). Second, beneﬁciaries with other
cancers (n ¼ 302) were excluded. Third, colorectal cancer (n ¼ 712)
diagnosed before the end of 1997 were also excluded to make sure
that all the subjects included were newly diagnosed with invasive
colorectal cancer, and the diagnosis was veriﬁed by the NHI registry
of catastrophic illnesses during 1998e2008. All patients who are
registered to have a catastrophic illness are exempted from all co-
payments. To be registered as such, patients must have the diag-
nosis of invasive colorectal cancer (ICD-9 code 153-154) validated
by tissue pathology. Finally, 2846 CRC survivors were included in
the study.2.2. Traditional Chinese medicine
For the purpose of studying the use of CHPs, we downloaded the
claims data, which is a sub-ﬁle in the data ﬁle of ambulatory care
expenditures by visits provided by BNHI, for reimbursed CHPs. The
corresponding information regarding the CHP was then obtained
from the DCMP website (Department of Chinese Medicine and
Pharmacy, Ministry of Health and Welfare, Taiwan), including the
name of each herb, the proportion of each constituent of the
mixture, the date and period of approval for the drug, the DCMP
manufacturer code, and the name of the CHP manufacturer. All
CHPs with the same DCMP standard formula are classiﬁed in theTable 1
Demographic characteristics and results of multiple logistic regression showing the adjus
cancer from the one million random sample of the National Health Insurance Research D
Characteristics CHPa non-users
No. of cases 1632
CHPd for colorectal cancer e
Gender
Male 996 (61.0)
Female 636 (39.0)
Age at diagnosis (years) 65.9 ± 13.5
39 71 (4.4)
40e49 146 (8.9)
50e59 276 (16.9)
60e69 393 (24.1)
70e79 520 (31.9)
 80 226 (13.8)
Insured region
Taipei city 313 (19.2)
Kaohsiung city 107 (6.6)
Northern Taiwan (exclude Taipei city) 477 (29.2)
Central Taiwan 251 (15.4)
Southern Taiwan (exclude Kaohsiung city) 442 (27.1)
Eastern Taiwan (include Outlying islands) 42 (2.6)
Location of colorectal cancere
Right colon 261 (16.0)
Left colon 179 (11.0)
Sigmoid colon 322 (19.7)
Rectum 696 (42.6)
Others, unspeciﬁed 174 (10.7)
Cancer treatment modalities
No treatment 157 (9.6)
Surgery only 734 (45.0)
Chemotherapy only 78 (4.8)
Surgery plus chemotherapy 663 (40.6)
a CHP: Chinese herbal product.
b aOR: adjusted odds ratio, also adjusted for comorbidities such as diabetes mellitus, h
c CI: conﬁdence interval.
d CHP: Chinese herbal products.
e Right: Appendix vermiformis, Cecum, Ascending colon, Hepatic ﬂexure; Left: Tran
Rectum; Other: Anal canal, Anus, and unspeciﬁed site.
Please cite this article in press as: Wu C-T, et al., Demographic and med
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dx.doi.org/10.1016/j.jtcme.2016.07.001same category, regardless of slight variations in the products
among different CHP manufacturers.20
2.3. Study variables
To determine the key independent variables for the utilization of
CHP among CRC survivors, we selected the demographic factors
according to previous studies.21e24 Patients were classiﬁed, based
on age, into one of six groups, as follows: 39, 40e49, 50e59,
60e69, 70e79, and 80 years. The geographic areas of Taiwan in
which patients resided were classiﬁed as one of the following six
regions: Taipei city, Kaohsiung city, Northern (exclude Taipei city),
Central, Southern Taiwan (exclude Kaohsiung city), and Eastern
Taiwan (include Outlying islands). We also searched the NHIRD
database for diagnosis and treatment records related to CRC as
independent variables. The locations of CRC were divided into ﬁve
types: right colon, left colon, sigmoid colon, rectum, and site un-
speciﬁed. The NHIRD contained all details related to the afore-
mentioned variables and cancer treatment modalities for treating
colorectal cancer. Then, for the ﬁnal analysis, we categorised the
types of cancer treatment modalities used as follows: no treatment,
surgery only, chemotherapy only, and surgery plus chemotherapy.
2.4. Statistical analysis
Descriptive statistics with chi-square test results are summa-
rized as shown in Table 1. Multiple logistic regression was con-
ducted to evaluate the factors that correlated with CHP use, byted odds ratio and 95% conﬁdence interval of cases with newly diagnosed colorectal
atabase from 1998 to 2008 in Taiwan.
CHP users aORb (95% CIc) p of Chi-square
1214
244
<0.0001
625 (51.5) 1
589 (48.5) 1.51 (1.29e1.76)
62.7 ± 13.0 <0.0001
59 (4.9) 0.89 (0.60e1.31)
143 (11.8) 1.04 (0.78e1.39)
259 (21.3) 1
345 (28.4) 0.94 (0.75e1.18)
309 (25.5) 0.63 (0.51e0.79)
99 (8.2) 0.46 (0.34e0.62)
0.0137
241 (19.9) 1
88 (7.2) 0.99 (0.71e1.38)
311 (25.6) 0.84 (0.67e1.06)
243 (20.0) 1.22 (0.95e1.56)
298 (24.5) 0.84 (0.67e1.05)
33 (2.7) 1.00 (0.61e1.65)
0.1554
164 (13.5) 1
115 (9.5) 0.98 (0.72e1.34)
264 (21.7) 1.30 (1.00e1.69)
528 (43.5) 1.22 (0.97e1.54)
143 (11.8) 1.40 (1.02e1.93)
0.0111
118 (9.7) 1
539 (44.4) 1.05 (0.79e1.39)
30 (2.5) 0.51 (0.31e0.83)
527 (43.4) 1.04 (0.78e1.38)
yperlipidemia, hypertension, crohn’s disease and ulcerative colitis.
sverse colon, Splenic ﬂexure, Descending colon; Rectum: Rectosigmoid junction,
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Table 2
Frequency distribution of Chinese herbal product visits by major disease categories
according to ICD-9-CM diagnosis codes in cases with colorectal cancer from 1998 to
2008 in Taiwan.
Major disease category ICD-9-CM codes Prescriptions of
Chinese herbal
product (%)
Infectious and parasitic diseases 001-139 1347 (1.2)
Neoplasms 140-239 34,965 (31.5)
Colorectal cancer 153-154 33,512 (30.2)
Other cancers (remainders of
neoplasms)
1453 (1.3)
Endocrine, nutritional and
metabolic diseases, and
immunity disorders
240-279 1256 (1.1)
Mental disorders 290-319 713 (0.6)
Diseases of the nervous system
and sense organs
320-389 2881 (2.6)
Diseases of the circulatory system 390-459 4010 (3.6)
Diseases of the respiratory system 460-519 10,575 (9.5)
Diseases of the digestive system 520-579 16,671 (15.0)
Diseases of the genitourinary system 580-629 3527 (3.2)
Diseases of the skin and subcutaneous
tissue
680-709 1988 (1.8)
Diseases of the musculoskeletal
system and connective tissue
710-739 9590 (8.6)
Symptoms, signs, and ill-deﬁned
conditions
780-799 20,499 (18.5)
Injury and poisoning 800-999 2158 (1.9)
Supplementary classiﬁcationb V01-V82,
E800-E999
153 (0.1)
Othersa 686 (0.6)
Total 111,019 (100.0)
a Others include ICD-9-CM codes 280-289, 630-677, 740-759, 760-779 and
missing/error data.
b Supplementary classiﬁcation of factors inﬂuencing health status and contact
with health service, external causes of injury and poisoning.
C.-T. Wu et al. / Journal of Traditional and Complementary Medicine xxx (2016) 1e74using the odds ratio (usually abbreviated “aORs”) adjusted for de-
mographic factors, location of colorectal cancer, cancer treatment
modalities, and comorbidities as the predicted values of people
who is more likely to be a CHP user. Potential predictors (cova-
riates) were risk factors which may increase the chance of using
CHP (diabetes mellitus, hypertension, dyslipidemia, crohn's dis-
ease, and ulcerative colitis), demographic factors (gender, age at
diagnosis, insured salaries, and insured regions), location of colo-
rectal cancer, and cancer treatment modalities. The following 3
models corresponding to three possible underlying biological sit-
uations regarding the CHP use across multiple conditions were
tested: model 1, adjusted for the demographic factors (age, gender,
insured salaries, insured region); model 2, adjusted for the de-
mographic factors, location of colorectal cancer, cancer treatment
modalities, and risk factors (diabetes mellitus, hypertension, dys-
lipidemia, crohn's disease, ulcerative colitis); model 3, adjusted for
the demographic factors, location of colorectal cancer, and cancer
treatment modalities. CRC survivors aged 50e59 was set as a
reference category in the variable “age at diagnosis” because the
sharply increasing age-speciﬁc incidence of colorectal cancer from
around age 50 was reported.25 “Male” and “Taipei city” were set as
reference categories in the other demographic covariates. The value
of the model was tested with the likelihood ratio test. It can be
assessed by comparing the ﬁt of the two models with and without
the independent variables. Overall ﬁt of model 3 shows a strong
relationship between most of the independent variables, taken
together, and dependent variable. A signiﬁcance level of a ¼ 0.05
was selected. The statistical software SAS 9.2 was used for data
management and analysis.
3. Results
Data analysis consisted of descriptive statistics, including the
prescription rates of the CHP users stratiﬁed by patient's de-
mographic characteristics (Table 1), indications for the prescription
of CHP (Table 2), and the most frequently prescribed herbal for-
mulas for treating CRC (Table 3). Primary indications were classiﬁed
according to their ICD-9 code. The diagnoses were coded according
to the ICD-9 and grouped into a series of distinct broad disease
categories. For example, ICD-9 codes 460-519 were classiﬁed as
diseases of the respiratory system; codes 780-799 were grouped as
symptoms, signs, and ill-deﬁned conditions, and codes 520-579
were classiﬁed as diseases of the digestive system. The potential
effects of Chinese herbs Ginseng Radix, Astragali Radix contained in
ten most commonly prescribed CHPs were shown in Table 4.14,15
The database of outpatient claims contained information on 2846
CRC survivors from 1998 to 2008. Prevalence of CRC on the right
colon, left colon, sigmoid colon, rectum and site unspeciﬁed was
14.9%, 10.3%, 20.6%, 43.0%, and 11.1%, respectively. The male-to-
female sex ratio for CRC was 1.32 in Taiwan and rectum was the
most common site of involvement, which is in line with previous
study.2 Among them, 1214 (42.7%) CRC survivors took Chinese
herbal products. Most CHP users (90.3%) also received cancer
treatment. Details on the demographic distribution of CHP users
and non-users are provided in Table 1. The mean age of CHP non-
users was higher than that of CHP users. There were more CHP
users than CHP non-users who were residing in central Taiwan.
Adjusted odds ratios (aORs) and 95% conﬁdence intervals (95%
CIs) obtained bymultiple logistic regression are also summarized in
Table 1. Females were more likely to use CHP. Compared with the
age group of 50e59 years (aOR ¼ 1.00), there were no signiﬁcant
differences in ages between CHP users and CHP non-users except
those aged 70 years and above who were more likely to be CHP
non-users. There was also no signiﬁcant difference or trend among
CRC survivors with multiple chronic conditions, in different incomePlease cite this article in press as: Wu C-T, et al., Demographic and med
colorectal cancer survivors: A nationwide database study in Taiwan, J
dx.doi.org/10.1016/j.jtcme.2016.07.001groups, and in use of cancer treatment between CHP users and non-
users.
Chinese herbal medicines were prescribed in 111,019 of visits
made by CRC survivors to TCM doctors. Analysis of the major dis-
ease categories for all TCM visits of CRC survivors are summarized
in Table 2, which show that “colorectal cancer” was the most
common reason for using CHP, followed by “symptoms, signs, and
ill-deﬁned conditions” and “diseases of the digestive system”. De-
tails on themost frequently prescribed CHP for treating CRC by TCM
doctors are provided in Table 3. As can be seen, Costusroot and
Amomum Six Gentlemen Decoction is the most frequently pre-
scribed CHP, followed by Ginseng, Poria, and White Atractylodes
Powder (參苓白朮散 shen líng bai zhú sǎn) and Center-
Supplementing Qi-Boosting Decoction (補中益氣湯 bǔ zhong yì qì
tang). Among the top 10 most frequently prescribed CHP, six con-
taining Ginseng Radix (人參, Panax ginseng) and two containing
Astragali Radix (黃耆, Astragalus membranaceus) of various doses
were identiﬁed.
Although over 1214 (42.7%) CRC survivors had used CHP as the
major method of treatment from 1998 to 2008, only about 20.1%
(n ¼ 244) of them sought CHP with the intent of either treating
their colorectal cancer or relieving the treatment-related side ef-
fects. CHP was prescribed in addition to surgery, and/or chemo-
therapy, and appeared to be used as an adjunct to conventional
treatment for cancer, rather than as alternatives.4. Discussion
Previous studies reported that approximately 75% of CRC sur-
vivors used CAM therapies.4 However, the information of CAM
therapies including TCM was collected via self-reportedication characteristics of traditional Chinese medicine users among
ournal of Traditional and Complementary Medicine (2016), http://
Table 3
Top 10 herbal formulas prescribed by TCM doctors for treating colorectal cancer among colorectal cancer patients from 1998 to 2008 in Taiwan.
Herbal formula Pinyin transliteration Person-day of prescriptions Average daily dose (g)
Costusroot and Amomum Six Gentlemen Decoction Xiang-Sha-Liu-Jun-Zi-Tang 3893 4.3
Ginseng, Poria, and White Atractylodes Powder Shen-Ling-Bai-Zhu-San 2794 4.9
Center-Supplementing Qi-Boosting Decoction Bu-Zhong-Yi-Qi-Tang 2592 3.2
Pinellia Heart-Draining Decoction Ban-Xia-Xie-Xin-Tang 2435 3.1
Supplemented Free Wanderer Powder Jia-Wei-Xiao-Yao-San 2293 4.4
Life Saver Kidney Qi Pill Ji-Sheng-Shen-Qi-Wan 2280 3.8
Spleen-Returning Decoction Gui-Pi-Tang 1944 3.4
Honey-Fried Licorice Decoction Zhi-Gan-Cao-Tang 1760 2.7
Stomach-Calming Powder Ping-Wei-San 1720 2.5
Lycium Berry, Chrysanthemum, and Rehmannia Pill Qi-Ju-Di-Huang-Wan 1416 3.1
C.-T. Wu et al. / Journal of Traditional and Complementary Medicine xxx (2016) 1e7 5questionnaire, which represented the patients' own perception and
expectation of the prescribed treatment. The strength of the pre-
sent data is the perspective of TCM doctors concerning the treat-
ment prescribed must be in line with the requirement of the NHI in
Taiwan. They had to follow the standard diagnoses using the ICD-9-
CM coding system when claiming reimbursement; and CRC survi-
vors are exempted from all copayments once TCM doctors coded
their diagnoses as ICD-9 code 153.0e154.1 (malignant neoplasm of
colon and rectum) to the NHI bureau. Therefore we can rule out the
possibility of recall bias. Although the present ﬁndings cannot be
generalized to the comprehensive usage of various types of CAM,
the present study using a random national-level sample revealedTable 4
The composition of the top 10 herbal formulas prescribed by TCM doctors for treating co
Herbal formula Composition
Costusroot and Amomum Six
Gentlemen Decoction
Ginseng Radix (Panax ginseng)a, A
(Wolﬁporia cocos), Citri Reticulata
Radix (Aucklandia lappa), Amomi
Zingiberis Rhizoma (Zingiber ofﬁc
Ginseng, Poria, and White
Atractylodes Powder
Ginseng Radix (Panax ginseng)a,
(Wolﬁporia cocos), Amomi Fructu
(Dioscorea polystachya), Nelumb
Radix (Platycodon grandiﬂorum)
Center-Supplementing
Qi-Boosting Decoction
Ginseng Radix (Panax ginseng)a,
membranaceus)b, Atractylodis M
Bupleuri Radix (Bupleurum chine
(Glycyrrhiza uralensis)
Pinellia Heart-Draining Decoction Ginseng Radix (Panax ginseng)a,
Coptidis Rhizoma (Coptis chinens
ofﬁcinale), Jujubae Fructus (Zizip
Supplemented Free Wanderer Powder Angelicae Sinensis Radix (Angelic
Poria (Wolﬁporia cocos), Gardeni
Paeoniae Radix (Paeonia lactiﬂora
Glycyrrhizae Radix (Glycyrrhiza u
Life Saver Kidney Qi Pill Rehmanniae Radix (Rehmannia g
(Cornus ofﬁcinalis), Alismatis Rhi
(Paeonia suffruticosa), Cinnamom
Achyranthis Bidentatae Radix (Ac
Spleen-Returning Decoction Ginseng Radix (Panax ginseng)a,
membranaceus)b, Atractylodis M
Aucklandiae Radix (Aucklandia la
(Polygala tenuifolia), Longan Arill
Zingiberis Rhizoma (Zingiber ofﬁ
Honey-Fried Licorice Decoction Ginseng Radix (Panax ginseng)a,
(Cinnamomum cassia), Asini Cori
Cannabis Fructus (Cannabis sativ
(Zingiber ofﬁcinale), Jujubae Fruc
Stomach-Calming Powder Citri Reticulatae Pericarpium (Cit
Atractylodis Rhizoma (Atractylod
(Zingiber ofﬁcinale), Jujubae Fruc
Lycium Berry, Chrysanthemum,
and Rehmannia Pill
Rehmanniae Radix (Rehmannia g
(Cornus ofﬁcinalis), Alismatis Rhi
Lycii Fructus (Lycium barbarum),
a Ginseng Radix.
b Astragali Radix.
Please cite this article in press as: Wu C-T, et al., Demographic and med
colorectal cancer survivors: A nationwide database study in Taiwan, J
dx.doi.org/10.1016/j.jtcme.2016.07.001the prevalence in use of CHP prescribed by licensed TCM doctors for
treating colorectal cancer.
42.7% of CRC survivors in Taiwan have ever used herbal thera-
pies for relieving their discomfort during the study period. Only
8.6% of all CRC survivors were intending to use CHP for treating
their colorectal cancer. Although CHP as a unique traditional ther-
apy for various ailments has been used in Taiwan for over hundreds
of years, more than 92% of CHP users received standard colorectal
cancer treatment during the 11-year study period. The present
study found that, regardless of the sites of involvement in colorectal
cancer, the choice of any of the major medical options available to
CRC survivors was not associated with the use of CHPs. And, thelorectal cancer from 1998 to 2008 in Taiwan.
tractylodis Macrocephalae Rhizoma (Atractylodis Macrocephalae), Poria
e Pericarpium (Citrus reticulata), Pinelliae Rhizoma (Pinellia ternate), Aucklandiae
Fructus (Amomum villosum), Glycyrrhizae Radix (Glycyrrhiza uralensis),
inale), Jujubae Fructus (Ziziphus jujuba)
Atractylodis Macrocephalae Rhizoma (Atractylodis Macrocephalae), Poria
s (Amomum villosum), Lablab Semen (Doiichos iabiab), Dioscoreae Rhizoma
inis Semen (Nelumbo nucifera), Coicis Semen (Coix lacryma-jobi), Platycodonis
, Glycyrrhizae Radix (Glycyrrhiza uralensis), Jujubae Fructus (Ziziphus jujuba)
Angelicae Sinensis Radix (Angelica sinensis), Astragali Radix (Astragalus
acrocephalae Rhizoma, Citri Reticulatae Pericarpium (Citrus reticulata),
nse), Cimicifugae Rhizoma (Cimicifuga heracleifolia), Glycyrrhizae Radix
Pinelliae Rhizoma (Pinellia ternate), Scutellariae Radix (Scutellaria baicalensis),
is), Glycyrrhizae Radix (Glycyrrhiza uralensis), Zingiberis Rhizoma (Zingiber
hus jujuba)
a sinensis), Atractylodis Macrocephalae Rhizoma (Atractylodis Macrocephalae),
ae Fructus (Gardenia jasminoides), Menthae Herba (Mentha haplocaly),
), Bupleuri Radix (Bupleurum chinense), Moutan Cortex (Paeonia suffruticosa),
ralensis), Zingiberis Rhizoma (Zingiber ofﬁcinale)
lutinosa), Dioscoreae Rhizoma (Dioscorea polystachya), Corni Fructus
zoma (Alisma plantago-aquatica), Poria (Wolﬁporia cocos), Moutan Cortex
i Cortex (Cinnamomum cassia), Aconiti Radix Lateralis (Aconitum carmichaelii),
hyranthes bidentata), Plantaginis Semen (Plantago asiatica)
Angelicae Sinensis Radix (Angelica sinensis), Astragali Radix (Astragalus
acrocephalae Rhizoma (Atractylodis Macrocephalae), Poria (Wolﬁporia cocos),
ppa), Ziziphi Spinosi Semen (Ziziphus jujuba), Polygalae Radix
us (Dimocarpus longan), Glycyrrhizae Radix (Glycyrrhiza uralensis),
cinale), Jujubae Fructus (Ziziphus jujuba)
Rehmanniae Radix (Rehmannia glutinosa), Cinnamomi Ramulus
i Colla (Equus africanus asinus), Ophiopogonis Radix (Ophiopogon japonicus),
a), Glycyrrhizae Radix (Glycyrrhiza uralensis), Zingiberis Rhizoma
tus (Ziziphus jujuba)
rus reticulata), Magnoliae Ofﬁcinalis Cortex (Magnolia ofﬁcinalis),
es lancea), Glycyrrhizae Radix (Glycyrrhiza uralensis), Zingiberis Rhizoma
tus (Ziziphus jujuba)
lutinosa), Dioscoreae Rhizoma (Dioscorea polystachya), Corni Fructus
zoma (Alisma plantago-aquatica), Poria, Moutan Cortex (Paeonia suffruticosa),
Chrysanthemi Flos (Chrysanthemum morifolium)
ication characteristics of traditional Chinese medicine users among
ournal of Traditional and Complementary Medicine (2016), http://
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receiving different types of colorectal cancer treatments was not
associated with deciding whether to visit TCM doctors. Possibly a
fear of the side effects of cancer treatment, together with the stress
of recurrent local and metastatic diseases following initial “cura-
tive” therapy,26,27 is a motivation for CRC survivors to use CHPs in
Taiwan. Hence, we inferred that CHP for CRC survivors in Taiwan
was generally used as adjuncts to cancer treatment, rather than as
replacements for it.
The present ﬁndings show that, among CRC survivors, females
and those aged 40e49 years were more likely to be CHP users than
males and other age groups as shown in Table 1. As shown in
Table 2, “colorectal cancer” was the most common reason for using
CHP (33,512). Further analysis found that TCM doctors tended to
use Chinese herbal remedies targeting symptom relief as well as
gastrointestinal disorders that might be the uncomfortable side
effects of cancer treatment. The results indicate that, besides
colorectal cancer care, health care providers should pay more
attention to the general health conditions of patients suffering from
either cancer-derived or cancer treatment induced symptoms and
provide proactive recommendations for these medical needs.
Costusroot and Amomum Six Gentlemen Decoction and
Ginseng, Poria, and White Atractyodest Powder were the two most
frequently prescribed formulas for treating colorectal cancer
among CRC survivors, which are all derivatives of Four Gentlemen
Decoction (四君子湯 sì jun zǐ tang), are prescribed to alleviate
various common symptoms of gastrointestinal disorders, namely
vomit, lump-like feeling in the abdomen, poor appetite, abdominal
distention and pain, emaciation, fatigue, or turgidity. Four Gentle-
men Decoction has a long history of use as part of the traditional
Chinese pharmacopoeia and was ﬁrst documented in the classical
Chinese text Tai-Ping Imperial Grace Pharmacy Formulas (太平惠民
和劑局方 tai píng huì mín he jì jú fang) approximately 1107 A.D. In
the classical literature Costusroot and Amomum Six Gentlemen
Decoction is mainly used for treatments of phlegm and retained
ﬂuid due to Qi deﬁciency, incoordination between the spleen and
the stomach, and other derivative symptoms and signs, while,
Ginseng, Poria, andWhite Atractyodest Powder is said to invigorate
spleen, replenish Qi, and eliminate dampness to relieve indigestion,
distention and fullness in chest, borborygmus, diarrhea, myas-
thenia of limbs, sallow complexion, and emaciation. Other
commonly prescribed formulas are associated with relieving the
focal distention or fullness in the stomach along with vomiting,
nausea, loose stool or poor appetite (Pinellia Heart-Draining
Decoction (半夏瀉心湯 ban xia xie xın tang); Supplemented Free
Wanderer Powder (加味逍遙散 jia wei xiao yao sǎn)), with a
distention in the abdomen along with belching, a desire to sleep,
and fatigue (Stomach-Calming Powder (平胃散 píng wei sǎn);
Center-Supplementing Qi-Boosting Decoction) or with ﬂaccidity,
with a distention in the abdomen along with low leg edema Life
Saver Kidney Qi Pill (濟生腎氣丸 jì sheng shen qì wan), with
insomnia, forgetfulness due to Qi deﬁciency (Spleen-Returning
Decoction (歸脾湯 guı pí tang)), or with anemia, palpitation, and
short of breath (Honey-fried Licorice Combination (炙甘草湯 zhì
gan cǎo tang)), or with blurred vision (Lycium Berry, Chrysan-
themum, and Rehmannia Pill (杞菊地黃丸 qǐ jú dì huang wan)).
Among the top 10 most frequently prescribed CHP for treating
colorectal cancer, seven have been documented to have potential
beneﬁcial effects on gastrointestinal-related symptoms. It is
apparent from this study that TCM doctors in Taiwan prescribed
herbal therapies mainly to reduce gastrointestinal-related symp-
tomatic discomfort. Although clinical studies on various herbs have
shown promising effects and herbal medicine has been prescribed
safely by professionals in Taiwan for many years, there is as yet
insufﬁcient evidence to allow a conclusion to be reached regardingPlease cite this article in press as: Wu C-T, et al., Demographic and med
colorectal cancer survivors: A nationwide database study in Taiwan, J
dx.doi.org/10.1016/j.jtcme.2016.07.001the cost-effectiveness of the aforementioned formulas in relation to
the anticancer effects and the provision of symptomatic relief
among CRC survivors. Further studies are warranted to assess the
formulas found to be generally used by TCM doctors in this study
and to determine whether they should be used as an add-on
treatment for CRC survivors receiving conventional anticancer
treatment.28
The present study has four limitations. Firstly, because the
identities of the patients were encrypted and thus not available in
the NHI reimbursement database, we were unable to obtain any
histopathology reports to verify the diagnoses. However, because
the registration of colorectal cancer as a catastrophic illness is
approved on the basis of pathology and/or cytology evidence and is
followed by a full waiver of copayment, such a diagnosis is made
only after very serious review and is generally accurate. We have
included all patients who were newly diagnosed with colorectal
cancer between 1998 and 2008 from a simple random sample of
one million subjects among the insured general population and the
rate of insured individuals has been consistently above 96% since
1997. Therefore we can rule out the possibility of selection bias.
Secondly, this study did not include Chinese herbal remedies pur-
chased directly from TCM herbal pharmacies, nor did we include
health foods containing herbs. Thus, the frequency of CHP utiliza-
tion might have been underestimated. However, because the NHI
system has a comprehensive coverage for TCM prescriptions, which
is generally less costly than the cost of herbs sold in Taiwan's
markets, the likelihood is that subjects purchased large quantities
of other herbs outside the NHI database is not high. Thirdly, we are
unable to draw any conclusion about the relationship between the
severity of the CRC-related symptoms and CHP utilization for lack
of actual clinical data. Lastly, our study is its retrospective nature or
lack of a randomized placebo group. Thus, great caution is neces-
sary in interpreting results of the most commonly prescribed Chi-
nese formulas obtained in present study due to the high likelihood
of a placebo effect. And, further research is needed to determine the
safety and efﬁcacy of these CHPs.
5. Conclusions
It is apparent that our ﬁndings may have implications for phy-
sicians attending to CRC survivors. Our results suggest that, under
the co-existence of the conventional medical treatments and TCM,
most CRC survivors consumedherbal therapieswith the intention of
relieving their gastrointestinal disorders, rather than rejecting
standard cancer treatments. Recognizing the use of CHP, exploring
potential interactions and adverse effects, and integrating both
approaches might be more beneﬁcial to the overall health, or sur-
vival and quality of life, of CRC survivors. Thus, health care providers
had better proactively explore a personalized optimal treatment for
CRC survivors, as well as attend to the patients' cancer-related or
cancer treatment-induced gastrointestinal disorders.
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